AstraZeneca Confident About Evusheld's Future Growth

As Next-Generation Version Moves Towards Clinic

Now approved for the treatment as well as the prevention of COVID-19 in the EU and Japan, the UK major’s antibody combo passed the $500m sales barrier in the third quarter and CEO Pascal Soriot is confident that growth will continue.

AstraZeneca
• Source: Shutterstock: Elzbieta Krzysztof

Sales of AstraZeneca PLC's vaccine Vaxzevria may be dwindling but its COVID-19 antibody cocktail Evusheld is selling well and will continue to do so, especially if an improved version gets to market next year.

That is the view of CEO Pascal Soriot who spoke the media on 10 November as AstraZeneca presented a strong...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip